Hybrid Organ GmbH

is a Berlin-based biomed company engaged in the development and commercialization of advanced cell culture bioreactors. The company´s patented core technologies serve as a platform for a wide range of potential products in numerous medical markets. They address both clinical needs in the field of cell based therapies, and research needs in stem cell technology for hybrid organ development. Our primary focus is on liver therapy.

Liver Therapy

We all hope to enjoy a long and healthy life. Despite great advances in medicine, liver disease remains the fourth leading cause of death. Hybrid Organ, one of the leading companies in medical bioreactor development, continues to make a substantial contribution to the treatment of liver disease. Our first commercial product is the Modular Extracorporeal Liver System - MELS - for clinical therapy in liver intensive care units. The MELS serves as an innovative platform for liver support technology. It enables temporary extracorporeal support of patients in severe liver failure. A modular concept allows treatment with different levels of complexity for relevant indications of liver injury. The most complex module enables the utilization of liver cells in bioreactor culture. This hybrid liver module performs synthesis, metabolism and regulation of the failing organ. The system has already undergone initial testing in therapy, and is currently the focus of clinical studies.